US/UK/Canada

Share

Contacts

  • Ulf Hannelius

    CEO


    Box 7349, SE-103 90 Stockholm
    +46 8 661 00 26
    +46 8 661 63 68
    https://www.diamyd.com

    • Links

    Quotes

    The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.
    Ulf Hannelius, CEO
    Our top strategic priority is to prepare for a marketing application for Diamyd®
    Ulf Hannelius, CEO
    Pick a time period -
    Tags ( Active)

    30 month results from DIABGAD-1 support effect after partial remission phase

    Results after 30 months of the investigator initiated pilot trial DIABGAD-1 show that treatment with the diabetes vaccine Diamyd® in combination with vitamin D and ibuprofen has a good safety profile and no serious related side effects. With the entire trial period taken into account, no significant difference in the ability to produce insulin was seen between the patient groups receiving active and placebo treatment. However, after the initial period, (partial remission phase or honeymoon period), a significant positive clinical effect was seen in the group receiving active treatment

    Diamyd Medical provides update on clinical studies with Diamyd®

    Diamyd Medical (Nasdaq First North, Stockholm, DMYD B) participates in six clinical studies with the diabetes vaccine Diamyd® for the treatment and prevention of type 1 diabetes. The Company announced today that yet another of these, the phase II study EDCR IIa now is fully enrolled and that results from a first evaluation after 6 months are estimated to be presented during the second quarter of 2017. The Company also announced that results from the placebo-controlled prevention study DiAPREV-IT 1 are expected to be presented during the first quarter of 2017.All 20 patients are now included

    Preliminary 15-month results from DIABGAD – a 30-month pilot study with the diabetes vaccine Diamyd® in combination with vitamin D and ibuprofen

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced from a clinical investigator-initiated pilot study, DIABGAD-1, that the diabetes vaccine Diamyd® in combination with vitamin D and ibuprofen after 15 months has a good safety profile with no reported serious side effects related to the treatment. The data shows that after the initial phase (referred to partial remission or the honeymoon phase), the group receiving placebo (non-active substance) lost their ability to produce insulin at a rate that was 2-3 times faster during the last 9 months of the 15-month period,

    Quarterly Report I 14/15

    September 2014 – November 2014, Diamyd Medical AB (publ), Fiscal year 2014/2015Reporting period, September 1, 2014 – November 30, 2014 · Net result amounted to MSEK -5.9 (-4.8) · Result per share amounted to SEK -0.3 (-0.2) · Cash flow from operating activities amounted to MSEK -5.8 (-4.3) · Liquid assets and short term investments amountedto MSEK 29.8 (61.0) at the end of the period Significant events during the reporting period · Diamyd-licensed technology, GABA in combination with Antigen Based Therapy, cures diabetes in pre-clinical model · Diamyd®

    Clinical study with Diamyd Medical’s diabetes vaccine fully recruited

    All participants have been included in a Phase II clinical study, DIABGAD-1, in which Diamyd Medical’s diabetes vaccine Diamyd®, in a unique combination with other drugs, is tested in children and adolescents recently diagnosed with type 1 diabetes. The first results from the researcher initiated study will thereby be available in the beginning of 2015.The study, DIABGAD-1, which is the first study of its kind, combines the diabetes vaccine Diamyd® with vitamin D and the anti-inflammatory drug ibuprofen. The Phase II study also evaluates the effect of a double dose of Diamyd® and the

    Quarterly Report I 13/14

    September 2013 – November 2013Diamyd Medical AB (publ), Fiscal year 2013/2014Reporting period September 1, 2013 – November 30, 2013 · Net sales amounted to MSEK 0.2 (0) · Loss before tax amounted to MSEK -4.8 ( profit 0.9) · Liquid assets and short term investments amounted to MSEK 61 (19) as of November 30, 2013 Significant events during the reporting period · Major owner increased holdings in Diamyd Medical Significant events after the reporting period · More than half of the patients treated in diabetes study with the diabetes vaccine Diamyd® · Diamyd

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media